Sun JK, et al. - Researchers assessed the durability of diabetic retinopathy (DR) improvements after a change in ranibizumab dosing from monthly to individualized pro re nata (PRN) therapy. After switching from ranibizumab monthly to an individualized best-corrected visual acuity– and optical coherence tomography–based ranibizumab 0.5 mg PRN dosing regimen, DR severity improvements with ranibizumab were maintained in the majority of patients in the open-label extension (OLE). Because DR worsening was experienced by nearly one-third of OLE patients not requiring further therapy for DME, once DME resolves, patients should be watched carefully for worsening of DR and possible need for more frequent follow-up and/or treatment of vision-threatening disease with anti-VEGF or other modalities.